Aviado · Research
Longevity Daily
Tuesday, August 18, 2026
Listen
Today's Brief
Today's edition centers on how our cells age — and what we might do about it. Our lead story from the Leibniz Institute identifies a phosphatidylcholine switch inside mitochondria that may explain the energy decline of aging, and hints at reversibility. A reanalysis of the landmark Look AHEAD trial makes the case that intensive lifestyle programs may quietly slow the biological clock even when they fail standard cardiovascular endpoints. And new pharmacokinetic data from aging mice raises a pointed question for the growing community of rapamycin users: is your dose actually getting through?
10 stories5 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Heart Trouble You Don't Feel May Be Accelerating Brain Aging — Especially If You Carry APOE ε4
A study in Alzheimer's & Dementia finds that subclinical cardiac dysfunction — heart problems that produce no obvious symptoms — is associated with both greater neurodegeneration at baseline and faster decline over time, specifically among people carrying the APOE ε4 variant. For the roughly one in four people with at least one copy of ε4, this means cardiac health isn't just about the heart: it may be directly determining how fast the brain ages. Even when you feel fine cardiovascularly, thorough cardiac monitoring could be one of the most underrated interventions available to ε4 carriers.
Read more →Supplements & Compounds
Older Bodies May Absorb Half as Much Rapamycin as Younger Ones — Raising Urgent Dosing Questions
A pharmacokinetics study from Istanbul found that aging mice absorb markedly less everolimus — a rapamycin analog — than young ones, with systemic drug exposure falling by more than half between youth and old age. This means the dose that produces therapeutic drug levels in a young animal may be substantially underdosing an older one, exactly when the drug is supposedly most needed. For the growing community of adults using rapamycin off-label for longevity, the findings raise a pointed question: is your standard dose actually getting through?
Read more →Peptides Are Everywhere in Longevity Communities — But the Scientists Who Discovered Them Are Alarmed
Research peptides — compounds originally developed for laboratory use — are being widely promoted by longevity seekers, gym enthusiasts, and wellness influencers as 'exercise in a bottle' and anti-aging agents, despite never being approved for human use. The scientists whose work spawned some of these compounds are alarmed: human safety data simply doesn't exist, and the quality of unregulated products varies wildly. If you're stacking peptides based on forum posts or influencer recommendations, this is a story worth reading before your next order.
Read more →Research & Papers
Scientists Find a Hidden Molecular Switch That Could Slow — or Reverse — Cellular Aging
Researchers at Germany's Leibniz Institute on Aging have identified phosphatidylcholine as a key regulator of mitochondrial health — a molecule that keeps the cell's energy networks flexible and able to respond to changing demands. As we age, phosphatidylcholine declines, causing mitochondrial networks to fragment: 'connections break down and currents stall,' as lead author Maria Ermolaeva puts it. The finding points to a specific, targetable mechanism behind the energy decline of aging — one the team describes as a 'finely branched power grid' that becomes increasingly damaged over time. Crucially, early evidence suggests the decline may be reversible, opening a concrete new front for longevity intervention.
Read more →Weekly Rapamycin Cocktail Rebuilds Aging Muscle in Cats — A Preview of Where Human Trials Are Heading
PURR-001 — a once-weekly oral capsule combining a low-dose rapamycin analog with mirtazapine and acarbose — produced measurable gains in body mass and back-muscle thickness in elderly sarcopenic cats over 12 weeks, outperforming placebo in a small randomized, double-blind, controlled trial. Cats develop age-related muscle loss in ways that closely mirror human sarcopenia, making them a more translatable model than rodents. The trial is small and animal-based, but it represents an early proof-of-concept for drug combination approaches targeting mTOR for age-related muscle loss — a strategy being actively explored for human trials.
Read more →Aviado Research: Latest In-Depth Longevity Analysis Now Available
Aviado Research's newest piece delivers an evidence-based examination of a key topic in longevity science, applying a critical lens to the primary literature to surface what's signal and what's noise. The full analysis is available for subscribers on the Aviado Research platform.
Read the full Aviado analysis →Lifestyle & Nutrition
Low Fitness in Old Age Nearly Doubles Late-Life Mortality Risk — The Numbers Are Hard to Ignore
A new analysis from Fight Aging! synthesizes large epidemiological data showing that older adults at the low end of physical fitness face roughly twice the late-life mortality risk of those at the high end — a magnitude that rivals or exceeds many pharmaceutical interventions. While human data can't fully prove causation, robust animal studies confirm that greater activity and fitness slow aging and extend life. If you track VO2 max or grip strength, this is your reminder that the gap between fit and unfit matters more than almost any biomarker you're currently watching.
Read more →The Weight-Loss Trial That 'Failed' May Have Been Quietly Slowing Aging All Along
The Look AHEAD trial famously showed that an intensive decade-long diet-and-exercise program couldn't reduce heart attacks or strokes in adults with type 2 diabetes — and was largely written off as a disappointment. Now, the original investigators argue the trial was an aging experiment in disguise: participants showed meaningful improvements in biological age markers that may simply not translate to short-term cardiovascular event rates. The reframing suggests we've been measuring lifestyle interventions by the wrong yardstick, and that longevity benefits may be accumulating even when the cardiometabolic numbers don't move.
Read more →Bryan Johnson Says Never Sharing a Bed Is Key to Longevity — The Research He Cited Tells a Different Story
Bryan Johnson revealed he has never shared a bed with his girlfriend Kate Tolo, citing sleep quality research to justify permanent separate sleeping arrangements. But Moneywise examined the studies Johnson referenced and found they offer limited support for the claim — while noting that a second bedroom carries a lifetime cost of roughly $170,517. It's a useful reminder that even well-intentioned biohackers can misread the evidence, and that the most rigorously supported sleep interventions — cool room, consistent schedule, darkness — don't require sleeping alone.
Read more →Industry & Policy
FDA Approves New PET Agent That Can Visualize Tau Tangles in Living Alzheimer's Patients
The FDA has approved Tauklarify (florquinitau F 18), a PET imaging agent that can detect tau neurofibrillary tangles — the toxic protein aggregates central to Alzheimer's pathology — in living adults being evaluated for the disease. Previously, tau pathology was largely confirmable only at autopsy; this approval gives clinicians a real-time window into disease progression and burden. For patients and families navigating Alzheimer's risk, the tool improves diagnostic precision and should accelerate clinical trials that use tau burden as a treatment endpoint.
Read more →